Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile CD274 positive
Therapy AZD2936
Indication/Tumor Type lung non-small cell carcinoma
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive lung non-small cell carcinoma predicted - sensitive AZD2936 Phase I Actionable In a Phase I trial (ARTEMIDE-01), AZD2936 treatment demonstrated acceptable safety and activity in patients with CD274 (PD-L1)-positive (TPS >/= 1%) advanced non-small cell lung cancer, with an overall response rate of 3.9% (3/76, 3 partial responses), stable disease in 39.5% (30/76), disease control rate (DCR) at 9 weeks of 43.4% (33/76), and a DCR at 27 weeks of 14.5% (11/76), with a duration of response of 2.1-6.4 mo (J Clin Oncol 41, 2023 (suppl 16; abstr 9050); NCT04995523). detail...
PubMed Id Reference Title Details
Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD2936, a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-experienced advanced/metastatic non-small-cell lung cancer (NSCLC): First report of ARTEMIDE-01. Full reference...